Oxford Vacmedix
Biotech & Life Sciences · Oxford, United Kingdom · Founded 2012
Develop therapeutic agents for the treatment of cancer MoreLess
Oxford Vacmedix, established in 2012 as a spinout from Oxford University, focuses on developing therapeutic agents for cancer treatment. The company's core innovation lies in the use of Recombinant Overlapping Peptides (ROP) to create new immunotherapy treatments. These agents activate the immune system to directly attack tumors, reducing the need for invasive treatments like chemotherapy and radiotherapy. This approach not only enhances the effectiveness of cancer treatment but also makes it more economical and easier to deliver.
Oxford Vacmedix primarily serves the healthcare and pharmaceutical sectors, targeting patients and medical professionals seeking advanced cancer treatment options. The company operates in the global biopharmaceutical market, which is characterized by high growth potential and significant demand for innovative cancer therapies.
The business model of Oxford Vacmedix involves extensive research and development (R&D) to create and refine its immunotherapy agents. The company generates revenue through grants, partnerships, and potential future sales of its therapeutic agents. Notably, the company has received funding from Innovate UK to support the clinical development of its lead cancer vaccine, OVM 200.
Keywords: cancer immunotherapy, Recombinant Overlapping Peptides, ROP, biopharmaceutical, oncology, tumor treatment, healthcare innovation, clinical development, OVM 200, Oxford University spinout.
Company overview
Oxford Vacmedix company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Oxford, United Kingdom
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 46.2
Valuation & funding
Oxford Vacmedix funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2025 | $1.5M | $6M | Undisclosed | ↗ |
| GRANT✓Other financing | Dec 2024 | $976K | — | UK Research and Innovation | — |
| GRANT✓Other financing | Apr 2022 | $647K | — | Undisclosed | — |
| GRANT✓Other financing | Dec 2019 | $383K | — | Undisclosed | — |
| SERIES A✓Equity / VC | Mar 2018 | $13M | $50M | Undisclosed | — |
| SEED✓Equity / VC | Jan 2013 | Oxford University Innovation | — | ||
| SPINOUT✓Other financing | Jan 2012 | Oxford University Innovation · University of Oxford | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Oxford Vacmedix website traffic
Latest recorded traffic for Oxford Vacmedix is 1.5K monthly website visits, down 6.3% over the last three months. Oxford Vacmedix's team grew 14.3% over the past year.
Comparisons
Oxford Vacmedix compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 SpireaAdvanced antibody-drug conjugate technology for cancer therapeutics |
Harrogate, United Kingdom | Operational | 8 | $3.8M | $13M |
 GelmetixInjectable polymer gel for non-surgical chronic pain treatment |
London, United Kingdom | Operational | |||
 DJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases |
Oxford, United Kingdom | Acquired | |||
 Argonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation |
Oxford, United Kingdom | Acquired | |||
 FemtogenixDNA-interactive payloads for antibody-drug conjugates |
St Albans, United Kingdom | Operational | |||
 AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
 IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational | |||
 KinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection |
Macclesfield, United Kingdom | Operational |
Talent graph
Oxford Vacmedix's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Oxford Vacmedix's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Oxford Vacmedix has talent and traffic
team presence
In the news
Latest news about Oxford Vacmedix
Recent press, funding announcements, and product moves mentioning Oxford Vacmedix — open to read from the original sources.
Market sentiment
What the market is saying about Oxford Vacmedix
An AI-synthesized read of the highest-engagement posts about Oxford Vacmedix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oxford Vacmedix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.